Skip to main content

Drug Interactions between infigratinib and Phyrago

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dasatinib infigratinib

Applies to: Phyrago (dasatinib) and infigratinib

Dasatinib may increase the blood levels of infigratinib in some patients. This may increase the frequency and severity of serious side effects such as infections; decreased red blood cell, white blood cell, and platelet counts; fever; abdominal pain; increased blood calcium and phosphate levels above normal; eye and vision problems; mouth sores and inflammation; diarrhea; redness, swelling, peeling or tenderness, mainly on the hands and feet ('hand-foot syndrome'); nails separating from the bed or poor formation of the nail; and changes in kidney function blood tests. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications your use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food interactions

Major

dasatinib food

Applies to: Phyrago (dasatinib)

Do not consume grapefruit or grapefruit juice during treatment with dasatinib. Grapefruit juice can significantly increase the blood levels and effects of dasatinib, which may result in excessive slowing of heart rate or other conduction disturbances and it may affect your bone marrow function, resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, heart palpitations, paleness, fatigue, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, blood in phlegm, weight loss, pain or burning during urination, red or inflamed skin, or body sores during treatment with dasatinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Major

infigratinib food

Applies to: infigratinib

Infigratinib should be taken on an empty stomach, at least 1 hour before or 2 hours after food. Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with infigratinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of infigratinib. This may increase the frequency and severity of serious side effects such as infections; decreased red blood cell, white blood cell, and platelet counts; fever; abdominal pain; increased blood calcium and phosphate levels above normal; eye and vision problems; mouth sores and inflammation; diarrhea; redness, swelling, peeling or tenderness, mainly on the hands and feet ('hand-foot syndrome'); nails separating from the bed or poor formation of the nail; and changes in kidney function blood tests. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.